Role for smaller drugmakers in flu vaccines sector
The market for seasonal influenza vaccines, which is set to hit $4.3 billion by 2025 and has traditionally been dominated by Big Pharma, will soon see smaller companies, such as Protein Sciences Corporation and Mitsubishi Tanabe Pharma, entering and increasing their presence across the competitive landscape.
According to research and consulting firm GlobalData’s new report, Sanofi (Euronext: SAN0, GlaxoSmithKline (LSE: GSK), AstraZeneca/ (LSE: AZN)/MedImmune, Novartis (NOVN: VX), and CSL Limited (ATX CSL)/Sequris have provided the majority of commercially available vaccines over the last decade. Smaller companies, such as Mylan (Nasdaq: MYL), have entered the competitive landscape, but have so far been unable to acquire a significant market share across the seven major pharmaceutical markets (7MM), which include the USA, France, Germany, Italy, Spain, the UK and Japan.
Changes as Novartis pulls out of sector
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze